丙型肝炎病毒-医学翻译-英翻中

winifred 2018年8月3日 20:47
翻译习作

原文 【Abstract】Objective To evaluated the efficacy and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) plus dasabuvir (DSV) coadministered with ribavirin (RBV) in adults with chronic genotype 1b hepatitis C virus(HCV) infection and compensated cirrhosis in Mainland China. Methods A phase 3, open-lable, multicenter trial was conducted in Mainland China, Taiwan and South Korea, in which the safety and efficacy of OBV/PTV/r plus DSV and RBV administered for 12 weeks were evaluated in treatment-naïve and treatment-experienced (interferon/pegylated interferon and ribavirin) adults with chronic genotype 1b HCV infection and compensated cirrhosis (fibrosis stage = F4). Efficacy was assessed by sustained virologic response identified at post-treatment week 12 and 24 (SVR12 and SVR24). Safety and efficacy were assessed in all patients receiving at least 1 dose of study drugs. Here we report sub-analysis data of patients from Mainland China.

译文 【摘要】目标:评估翁比他韦/帕利瑞韦/利托那韦(OBV/PTV/r)与达萨布韦 (DSV)、利巴韦林(RBV)共同应用于治疗中国大陆慢性1b型丙型肝炎病毒(HCV)及代偿性肝硬化的有效性和安全性。方法:A第三阶段,在中国大陆、台湾和韩国进行开放式、多中心试验,试验持续12周,在未接受过治疗及多次接受治疗(干扰素/聚乙二醇干扰素和利巴韦林)的成年慢性1b型丙型肝炎病毒(HCV)及代偿性肝硬化患者(纤维化阶段= F4)身上进行测试,评估OBV/PTV/r 与 DSV及RBV共同应用于治疗上述患者的安全性和有效性。治疗后第12周和第24周(SVR12、SVR24)进行持续病毒学反应评估其疗效。所有服用一剂以上研究药物的患者皆纳入安全性和有效性评估样本。在这里我们将汇报来自中国大陆的患者的子分析数据

0 likes